Pabak Mukhopadhyay
Overview
Explore the profile of Pabak Mukhopadhyay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
1874
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Baselga J, Campone M, Piccart M, Burris 3rd H, Rugo H, Sahmoud T, et al.
N Engl J Med
. 2011 Dec;
366(6):520-9.
PMID: 22149876
Background: Resistance to endocrine therapy in breast cancer is associated with activation of the mammalian target of rapamycin (mTOR) intracellular signaling pathway. In early studies, the mTOR inhibitor everolimus added...
2.
Andre F, Campone M, ORegan R, Manlius C, Massacesi C, Sahmoud T, et al.
J Clin Oncol
. 2010 Oct;
28(34):5110-5.
PMID: 20975068
Purpose: To determine the recommended dose of everolimus, a mammalian target of rapamycin inhibitor, combined with paclitaxel and trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic...
3.
McHutchison J, Lawitz E, Shiffman M, Muir A, Galler G, McCone J, et al.
N Engl J Med
. 2009 Jul;
361(6):580-93.
PMID: 19625712
Background: Treatment guidelines recommend the use of peginterferon alfa-2b or peginterferon alfa-2a in combination with ribavirin for chronic hepatitis C virus (HCV) infection. However, these regimens have not been adequately...
4.
Poynard T, Colombo M, Bruix J, Schiff E, Terg R, Flamm S, et al.
Gastroenterology
. 2009 Feb;
136(5):1618-28.e2.
PMID: 19208349
Background & Aims: Treatment with peginterferon alfa and ribavirin produces a sustained virologic response (SVR) in approximately 60% of hepatitis C virus (HCV)-infected patients. Alternate options are needed for patients...
5.
Jacobson I, Brown Jr R, Freilich B, Afdhal N, Kwo P, Santoro J, et al.
Hepatology
. 2007 Sep;
46(4):971-81.
PMID: 17894303
Unlabelled: This prospective, multicenter, community-based and academic-based, open-label, investigator-initiated, U.S. study evaluated efficacy and safety of pegylated interferon (PEG-IFN) alfa-2b plus a flat or weight-based dose of ribavirin (RBV) in...
6.
Cole B, Gelber R, Gelber S, Mukhopadhyay P
J Biopharm Stat
. 2004 Mar;
14(1):111-24.
PMID: 15027503
Quality of life is an important component in the evaluation of therapies, especially in advanced cancer. Methods available for the analysis of longitudinal quality-of-life data include linear mixed models (including...
7.
Melani L, Mills R, Hassman D, Lipetz R, Lipka L, Lebeaut A, et al.
Eur Heart J
. 2003 Apr;
24(8):717-28.
PMID: 12713766
Aims: To evaluate the efficacy and safety of ezetimibe 10 mg administered with pravastatin in patients with primary hypercholesterolemia. Methods And Results: After dietary stabilization, 2-12 week screening/washout period, and...
8.
Kerzner B, Corbelli J, Sharp S, Lipka L, Melani L, Lebeaut A, et al.
Am J Cardiol
. 2003 Feb;
91(4):418-24.
PMID: 12586255
This multicenter, randomized, double-blind, placebo-controlled clinical study assessed the efficacy and safety of ezetimibe administered with lovastatin in primary hypercholesterolemia. After dietary stabilization, a 2- to 12-week washout period, and...